The role of bisphosphonates in breast cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 1, Issue 2, 2003, Pages 232-241

  Theriault, Richard L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bisphosphonates; Breast neoplasms; Chemotherapy; Metastases; Osteoclast activity; Pamidronate; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; METASTASIS; REVIEW;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 33947502442     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2003.0022     Document Type: Article

References (88)

1. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
2. Giordano S, Buzdar A, Kau S-W et al. Improvement in breast cancer survival: Results from M. D. Anderson Cancer Center protocols from 1975-2000 (Abstr. #212). Proc Am Soc Clin Oncol 2002;21:54a.
3. Scheid V, Buzdar AU, Smith TL et al. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58:2589-2593.
4. Domchek SM, Younger J, Finkelstein DM et al. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89:363-368.
5. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
6. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991;9: 509-524.
7. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-340.
8. Hortobagyi GN, Libshitz HI, Seabold JE. Osseous metastases of breast cancer: Clinic, biochemical, radiographic, and stenographic evaluation of response to therapy. Cancer 1984;53: 577-582.
9. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-2044.
10. Libshitz HI. Hortobagyi GN. Radiographic evaluation of therapeutic response in bony metastases from breast cancer. Skeletal Radiol 1981;7:159-165.
11. Koenders PG, Beex LV, Kloppenborg PW et al. Human breast cancer: Survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat 1992;21:173-180.
12. Powell GJ, Southby J, Danks JA et al. Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res 1991;51:3059-3061.
13. Brandt DW, Wachsman W, Deftos LJ. Parathyroid hormonelike protein: Alternative messenger RNA splicing pathways in human cancer cell lines (Abstr). Cancer Res 1994;54:850.
14. Bundred NJ, Walker RA, Ratcliffe WA et al. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992;28:690-692.
15. Kissin MW, Henderson MA, Danks JA et al. Parathyroid hormone related protein in breast cancer of widely varying prognosis. Eur J Surg Oncol 1993;19:134-142.
16. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997;80:1572-1580.
17. Vargas SJ, Gillespie MT, Powell GJ et al. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res 1992;7:971-979.
18. Bundred NJ, Walker RA, Ratcliffe WA et al. A humoral role for parathyroid hormone-related peptide in breast cancer (Abstr. #12). Breast Cancer Res Treat 1991;99:159.
19. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80: 1546-1556.
20. de Vernejoul MC. Dynamics of bone remodelling: Biochemical and pathophysiological basis (Review). Eur J Clin Chem Clin Biochem 1996;34:729-734.
21. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer 1997;80:1538-1545.
22. Lowik CWGM, van der Pluijm G, Bloys H et al. Parathyroid hormone and PTH-like protein stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 1989;162:1546-1552.
23. Hauschka PV, Chen TL, Mavrakos AE. Polypeptide growth factors in bone matrix. Ciba Foundation Symp 1988;207-225.
24. Mundy GR, Bonewald LF. Role of TGFb in bone remodeling. Ann NY Acad Sci 1990;593:91-97.
25. Krane SM, Goldring MB, Goldring SR. Cytokines. Ciba Foundation Symp 1988;136:239.
26. Evans CE, Ward C, Braidman IP. Breast carcinomas synthesize factors which influence osteoblast-like cells independently of osteoclasts in vitro (Abstr). J Endocrinol 1991; 128:R5.
27. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
28. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANK ligand. Proc Natl Acad Sci USA 1988;95:3597-3602.
29. Hofbauer LC, Heufelder AE. Osteoprotegerin and its cognate ligand: A new paradigm of osteoclastogenesis. Eur J Endocrinol 1988;139:152-154.
30. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
31. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-3571.
32. Mundy GR, Yoneda T, Hiraga T. Zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin Oncol 2001;28:35-44.
33. Kanis JA. Rationale for the use of bisphosphonates in breast cancer. Acta Oncol 1996;35:61-67.
34. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease (Review). Drugs 1991;42:919-944.
35. Yoneda T, Michigami T, Yi B et al. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 1999;25:293-299.
36. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
37. Sasaki A, Boyce BF, Story B et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551-3557.
38. Sasaki A, Kitamura K, Alcalde RE et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 1998;77:279-285.
39. Dallas SL, Garrett R, Oyajobi BO et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999;93:1697-1706.
40. Jagdev SP, Coleman RE, Shipman CM et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001; 84:1126-1134.
41. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15: 2211-2221.
42. Lee MV, Fong EM, Singer FR et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-2608.
43. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
44. Gucalp R, Theriault RL, Gill I et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Int Med 1994;154:1935-1944.
45. Thiebaud D, Jaeger P, Jacquet AF et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988;6:762-768.
46. Nussbaum SR, Younger J, Vanderpol CJ et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg doses. Am J Med 1993;95:297-304.
47. Zysset E, Ammann P, Jenzer A et al. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner 1992;18:237-249.
48. Ralston SH, Gallagher SJ, Patel U et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989;2:1180.
49. Ryzen E, Martodam R, Troxell M et al. Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med 1985;145:449-452.
50. Schenk R, Eggli P, Fleisch H et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-349.
51. Tamanoi F, Kato-Stankiewicz J, Jiang C et al. Farnesylated proteins and cell cycle progression. J Cell Biochem 2001; 37(Suppl):64-70.
52. Cohen LH, Pieterman E, van Leeuwen RE et al. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol 2000;60: 1061-1068.
53. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-242.
54. Benford HL, McGowan NW, Helfrich MH et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-473.
55. Viereck V, Emons G, Lauck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-686.
56. Elomaa I, Blomqvist C, Porkka L et al. Treatment of skeletal disease in breast cancer: A controlled clodronate trial. Bone 1987;8(Suppl):S53-S56.
57. Paterson AHG, Ernst DS, Powles TJ et al. Treatment of skeletal disease in breast cancer with clodronate. Bone 1991; 12(Suppl):S25-S30.
58. Conte PF, Giannessi PG, Latreille J et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients. Ann Oncol 1994;5(Suppl 7):S41-S44.
59. van Holten-Verzantvoort A, Bijvoet OLM, Hermans J et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate treatment. Lancet 1987;2:983-985.
60. Hultborn R, Gundersen S, Ryden S et al. Efficacy of pamidronate in breast cancer with bone metastases: A randomized double-blind placebo controlled multicenter study. Acta Oncol 1996;35(Suppl 5):73-74.
61. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335: 1785-1791.
62. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854.
63. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
64. Carlson RW, Anderson BO, Bensinger W et al. Update: NCCN Practice Guidelines for the Treatment of Breast Cancer. Oncology (Huntingt) 1999;13:187-212.
65. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies (Review). Semin Oncol 2001;48:4-10.
66. Coxon FP, Helfrich MP, van't Hof R et al. Protein geranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-1476.
67. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome release in breast cancer cells. Br J Cancer 2002;86:1479-1486.
68. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
69. Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 1994;26:95-107.
70. Derenne S, Amiot M, Barille S et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-2056.
71. Marion G, Serre CM, Trzeciak MC et al. Bisphosphonates inhibit the platelet-aggregating activity of tumor cells, a process involved during hematogenous dissemination of metastatic cells (Abstr. T330). Bone 1998;23(Suppl 1):S279.
72. Boissier S, Magnetto S, Delmas PD et al. Bisphosphonates inhibit prostate and breast carcinoma cell invasion, but not tumor cell migration, through a mechanism independent of apoptosis induction (Abstr. #SA128). Bone 1998;23(Suppl 7):S558.
73. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
74. Rosen LS, Gordon D, Antonio BS et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
75. Rosen L, Gordon D, Dugan W et al. Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least 1 osteolytic lesion (Abstr. #629). Eur Soc Med Oncol Congr 2002; 18:22.
76. Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;6:357-363.
77. Diel IJ, Solomayer E, Gollan C et al. Bisphosphonates in the reduction of metastases in breast cancer - Results of the extended follow-up of the first study population (Abstr. #314). Proc Am Soc Clin Oncol 2000;19:82a.
78. Powles TJ, Paterson AHG, Nevantaus A et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer (Abstr. #468). Proc Am Soc Clin Oncol 1998;17:123a.
79. Powles T, Paterson S, Kanis JA et al. Randomized, placebocontrolled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-3224.
80. Saarto T, Blomqvist C, Virkkunen P et al. No reduction of bone metastases with adjuvant clodronate treatment in nodepositive breast cancer patients (Abstr. #489). Proc Am Soc Clin Oncol 1999;18:128a.
81. Saarto T, Blomqvist C, Virkkunen P et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-17.
82. Major PP, Lipton A, Berenson J et al. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000;88:6-14.
83. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002;4.
84. DesHarnais CL, Bajwa K, Markle JP et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001;7:545-551.
85. Hillner BE, Weeks JC, Desch CE et al. Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2000;18:72-79.
86. Saad F, Gleason DM, Murray R et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
87. Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95(Suppl):2S-4S.
88. Cook DL, Guyatt GH, Laupacis A et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992;102(Suppl):305S- 311S.